Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 19/20 | 0.66 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1190574 | 0.89 | PTGDR2 (0.53) | PTGDR2PTGDR | |
| SCHEMBL1191271 | 0.89 | PTGDR2 (0.74) | PTGDR2 | |
| SCHEMBL27748967 | 0.85 | PTGDR2 (0.49) | PTGDR2 | |
| SCHEMBL27748968 | 0.80 | PTGDR2 (0.46) | PTGDR2 | |
| Fevipiprant SCHEMBL29355753 | 0.80 | PTGDR2 (1.00) | PTGDR2 | |
| Fevipiprant SCHEMBL1940595 | 0.80 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1940977 | 0.79 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL1190673 | 0.79 | PTGDR2 (0.60) | PTGDR2 | |
| SCHEMBL3395183 | 0.77 | PTGDR2 (0.68) | PTGDR2PTGDR | |
| SCHEMBL27728079 | 0.76 | PTGDR2 (0.56) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888383-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-02-15 | — | — | US | disclosed |
| US-20090221578-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-09-03 | — | — | US | disclosed |
| CN-101351445-A | Bicyclic heteroyclic compounds as antiinflammatory or antiallergic agents | NOVARTIS AG (CH) | 2009-01-21 | — | — | CN | disclosed |
| EP-1971574-A2 | BICYCLIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY OR ANTIALLERGIC AGENTS | Novartis AG (CH) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007065684-A2 | BICYCLIC HETEROYCLIC COMPOUNDS AS ANTIINFLAMMATORY OR ANTIALLERGIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221578-A1 | Organic Compounds | DRD4, RDX, DRD1 | PTGDR2 618/4885PTGDR 151/4885AKR1C3 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.